ATNM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATNM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Actinium Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was $0.08 Mil.
Actinium Pharmaceuticals's COGS to Revenue for the three months ended in Dec. 2023 was 0.00.
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Actinium Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 was N/A%.
The historical data trend for Actinium Pharmaceuticals's COGS-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Actinium Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
COGS-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
Actinium Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
COGS-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
Actinium Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as
COGS to Revenue | = | Cost of Goods Sold | / | Revenue |
= | 0 | / | 0.081 | |
= | 0.00 |
Actinium Pharmaceuticals's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as
COGS to Revenue | = | Cost of Goods Sold | / | Revenue |
= | 0 | / | 0.081 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Actinium Pharmaceuticals (AMEX:ATNM) COGS-to-Revenue Explanation
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.
Actinium Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 is calculated as:
Gross Margin % | = | 1 | - | COGS to Revenue |
= | 1 | - | Cost of Goods Sold / Revenue | |
= | 1 | - | 0 / 0.081 | |
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.
Thank you for viewing the detailed overview of Actinium Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Sandesh Seth | director | 300 E 93RD STREET, #20-B, NEW YORK NY 10128 |
Steve O'loughlin | officer: VP, Finance and Corporate Dev. | 955 HARTMAN RUN ROAD, MORGANTOWN WV 26507 |
Dale L. Ludwig | officer: Chief Scientific Officer | 21 FERNWOOD ROAD, ROCKAWAY NJ 07866-2028 |
Jeffrey W. Chell | director | 521 MANDALAY AVENUE #708, CLEARWATER BEACH FL 33767 |
Ajit Shetty | director | 643 ZEEDIJK, KNOKKE C9 8300 |
Anil Kapur | officer: Chief Commercial Officer | 275 MADISON AVE, SUITE 702, NEW YORK NY 10016 |
Nitya G. Ray | officer: Executive Vice President | 14 BAYBURY COURT, EAST HANOVER NJ 07936 |
Mark Stanley Berger | officer: Chief Medical Officer | 140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024 |
Memorial Sloan-kettering Cancer Center | 10 percent owner | 1275 YORK AVE., NEW YORK NY 10065 |
Sergio Traversa | director | 138 CANTERBURY LN, BLUE BELL PA 19422 |
C. David Nicholson, | director | 103 CHILDS ROAD, BASKIN RIDGE NJ 07092 |
Kaushik J Dave | director, officer: President and CEO | 4 WATER STREET, EDISON NJ 08820 |
Richard I Steinhart | director | 125 ELM STREET, NEW CANAAN CT 06840 |
Ahlb Holdings, Llc | 10 percent owner | C/O MSKCC, 1275 YORK AVE., NEW YORK NY 10065 |
Actinium Holdings, Ltd. | 10 percent owner | C/O /O STERLING MANAGEMENT, LTD., P.O. BOX HM 29, HAMILTON HM CX D0 00000 |
From GuruFocus
By PRNewswire PRNewswire • 01-17-2023
By PRNewswire • 12-11-2023
By PRNewswire PRNewswire • 06-07-2023
By PRNewswire PRNewswire • 04-19-2023
By PRNewswire PRNewswire • 04-27-2023
By PRNewswire • 07-24-2023
By PRNewswire PRNewswire • 01-12-2023
By PRNewswire PRNewswire • 02-27-2023
By PRNewswire • 01-02-2024
By PRNewswire • 08-21-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.